Mechanisms of infliximab: the reverse side of a drug effect.

about

Infliximab and ulcerative colitis.Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications.Current state of biologicals in the management of systemic vasculitis.Infliximab in dermatological treatment: beyond psoriasis.

P2860

Q34503548-DF40BC2C-9304-4038-9B7A-95DB49AC8320 Q36587152-55507346-DCCD-448B-9398-A86ECEE27D38 Q36958331-35975FBC-5DAC-4476-85BD-04B21D647339 Q37032659-2771A150-353F-4AB6-9091-2B0F5B424F0D

P2860

Mechanisms of infliximab: the reverse side of a drug effect.

Item

http://www.wikidata.org/entity/Q35787649

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Mechanisms of infliximab: the reverse side of a drug effect.

@ast

Mechanisms of infliximab: the reverse side of a drug effect.

@en

type

Item

label

Mechanisms of infliximab: the reverse side of a drug effect.

@ast

Mechanisms of infliximab: the reverse side of a drug effect.

@en

prefLabel

Mechanisms of infliximab: the reverse side of a drug effect.

@ast

Mechanisms of infliximab: the reverse side of a drug effect.

@en

P1476

Mechanisms of infliximab: the reverse side of a drug effect.

@en

P2093

Georg H Waetzig

http://www.w3.org/2001/XMLSchema#string

Stefan Schreiber

http://www.w3.org/2001/XMLSchema#string

P2860

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor

Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells

Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha

Cytokine profiles of cultured microvascular endothelial cells from the human intestine

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor

The stress-activated protein kinase pathways.

P304

S38-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00054725-200402001-00009

http://www.w3.org/2001/XMLSchema#string

P478

10 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2004-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227977553

http://www.w3.org/2001/XMLSchema#string

P698

15168830

http://www.w3.org/2001/XMLSchema#string

Mechanisms of infliximab: the reverse side of a drug effect.

about

P2860

P2860

Mechanisms of infliximab: the reverse side of a drug effect.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698